FGFR3 and cancer: Other selective isoform FGFR2 and FGFR3 inhibitors continue in their clinical development and these studies may clarify the optimal strategies for drug the FGF/FGFR axis in cancer [NCT05544552, NCT04526106, NCT05614739 (30)].